Horama is a clinical-stage biopharmaceutical company developing gene therapy therapies based on vectors derived from a recombinant adeno-associated virus (rAAV) targeting rare diseases of the retina.
Horama focuses on the development of gene therapy products to rare ophthalmology pathologies with recombinant adeno-associated viral vectors for orphan blinding diseases.
Horama was founded in 2014 & is based in Paris, France.
Horama has a diversified portfolio of its gene therapy platform, of which 2 main programs benefit from orphan drug designations: HORA PDE6B (retinitis pigmentosa), including the Phase I / II clinical trial, which began in November 2017, and HORA-RLPB1 (RPA or Retinitis Ponctuée Albescente) currently in the preclinical phase.
Horama is backed by leading investors such as Kurma Partners, Idinvest Partners, V-Bio Ventures, GO CAPITAL etc..